Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
West Virginia patients are left in limbo over changing insurance coverage of obesity medications
Proponents say long-term savings could outweigh the cost — especially in West Virginia, which has the nation's highest rates ...
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
pulmonologyadvisor21h
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
BioSpace1h
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
FDA approves first ever medication for obstructive sleep apnea — here's what that means
Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...
Fierce Healthcare1d
Found introducing oral dissolvable GLP-1 tablet at reduced price
Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...
Wegovy to Zepbound: The Pros and Cons of Weight Loss Medications
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
Pharmaceutical Technology3d
Bivamelagon by Rhythm Pharmaceuticals for Obesity: Likelihood of Approval
Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...